Skip to Content

Join the 'Valganciclovir' group to help and get support from people like you.

Valganciclovir News

Antibodies May Hold Key to HIV Suppression

Posted 10 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions of an anti-HIV antibody known as VRC01. The antibody was safe and repressed blood levels of HIV for a short time before the virus reappeared, the researchers said. HIV is the virus that can lead to AIDS. "We were not expecting that we were going to see a prolonged repression, because it was only a single antibody," said co-study author Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. The next phase is to infuse two or three antibodies intermittently, and see if antiretroviral drugs can be withdrawn permanently, he explained. After regular intravenous infusions of VRC01, participants in the U.S. National Institutes of ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Kaletra, Valcyte, Entecavir, Norvir, Copegus, Tenofovir, Ribasphere

HIV May Hide in Tissues, Even After Treatment

Posted 27 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV in the blood and controls the disease. But the new findings suggest that HIV in the tissues may not cause AIDS but could contribute to the development of unrelated conditions, such as cancer and heart disease, according to the University of California, San Francisco (UCSF) researchers. "Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals," said study senior author Dr. Michael McGrath. "Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications," said McGrath. He is UCSF professor of laboratory medicine at the AIDS and Cancer ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Sovaldi, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Sofosbuvir, Famvir, Viread, Kaletra, Ribasphere, Entecavir, Valcyte, Norvir

Monkey Study Hints at Drug-Free Suppression of HIV

Posted 13 Oct 2016 by Drugs.com

THURSDAY, Oct. 13, 2016 – Scientists may have found a way to suppress an HIV-like infection in monkeys, without the need for ongoing drug therapy. The researchers added antibody therapy to standard drug treatment given to macaque monkeys infected with simian immunodeficiency virus (SIV). After three months, the animals were taken off the drugs, but their viral levels remained low to undetectable – for close to two years. Experts stressed that the animal findings need to be viewed with caution, and that many questions remain. But, they were also hopeful this could lead to a therapy that frees at least some people from their HIV drug regimens. An initial safety study has already started at the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The drug "cocktails" used to treat HIV – known as combined antiretroviral therapy (ART) – have changed the face of the ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Kaletra, Norvir, Entecavir, Tenofovir, Ribasphere, Copegus, Valcyte, Telaprevir

New HIV Treatment Shows Promise in Early Research

Posted 23 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 23, 2015 – Preliminary new research raises the prospect that a recently discovered antibody – an important component of the immune system – could be enlisted to boost the body's response to HIV, the virus that causes AIDS. A single injection of the antibody, currently dubbed VRC01, dramatically reduced the level of HIV in the blood of people who hadn't yet been given antiretroviral drug treatment (ART). ART is the current standard treatment for managing HIV infections, according to the study's authors from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases in Bethesda, Md. But in people who'd already been treated with ART, the antibody injection had no effect on HIV levels, presumably because the ART therapy had already reduced the levels of HIV virus in their blood, the researchers said. And the researchers were quick to note ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Victrelis, Famciclovir, Famvir, Viread, Oseltamivir, Kaletra, Norvir, Ribasphere, Tenofovir, Entecavir

FDA Lifts Ban on Blood Donations by Gay Men

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Gay and bisexual men who have abstained from sex for one year will now be allowed to donate blood in the United States. The new policy, announced Monday by the U.S. Food and Drug Administration, reverses a three-decades-old ban on donations from this group of men that traces back to the start of the AIDS epidemic. "The FDA's responsibility is to maintain a high level of blood product safety for people whose lives depend on it," FDA Acting Commissioner Stephen Ostroff said in an agency news release. "We have taken great care to ensure this policy revision is backed by sound science and continues to protect our blood supply." The FDA said it was changing its policy based on data from other countries that show allowing such donations would not increase the risk of HIV-tainted blood entering America's blood supply. FDA officials have estimated that about half of the ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Harvoni, HIV Infection, Valtrex, Anemia, Acyclovir, Tamiflu, Atripla, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Blood Transfusion, Zovirax, Truvada, Stribild, Triumeq, Complera, Baraclude

Health Tip: Understanding Antibiotics

Posted 9 Dec 2015 by Drugs.com

-- By taking an antibiotic as prescribed, you can get well faster and help prevent germs from becoming resistant to your medication. The U.S. Centers for Disease Control and Prevention offers these antibiotic guidelines: Never skip a dose of antibiotic. Always take it on schedule, as directed. Never stop taking an antibiotic early. Always take the entire prescription, unless your doctor tells you otherwise. Never save any antibiotic medication for a future illness. Never take an antibiotic that was prescribed for another person. Read more

Related support groups: Infections, Amoxicillin, Metronidazole, Doxycycline, Bacterial Infection, Cephalexin, Clindamycin, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Augmentin, Levaquin, Flagyl, Keflex, Zithromax, Valtrex, Trimethoprim, Sulfamethoxazole, Acyclovir

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Atripla, Hepatitis B, Sovaldi, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Truvada, Pegasys, Stribild, Complera, Triumeq, Baraclude, Victrelis, Famciclovir

Antiviral Drug May Extend Brain Cancer Survival, Researchers Say

Posted 4 Sep 2013 by Drugs.com

WEDNESDAY, Sept. 4 – A drug used against a common virus may lengthen the lives of people with a deadly form of brain cancer, a preliminary study suggests. Writing in the Sept. 5 issue of the New England Journal of Medicine, researchers reported on 50 patients who were given the antiviral drug valganciclovir (Valcyte) to help treat glioblastoma. The cancer is the most common form of brain tumor in adults, and it carries a dismal prognosis – with a typical survival of just over a year. These 50 patients, however, fared far better, researchers found. After two years, 62 percent were still alive. Of the 25 who took the antiviral continuously, 90 percent were still alive. That compared with just 18 percent of patients who received most of the same treatments – including surgery and chemotherapy – but did not take Valcyte. "These data are by far the best ever seen for these patients," ... Read more

Related support groups: Glioblastoma Multiforme, Valcyte, Valganciclovir

FDA Approves Longer Use of Valcyte for Adult Kidney Transplant Patients at High Risk of Developing Cytomegalovirus (CMV) Disease

Posted 11 Aug 2010 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 10, 2010 - Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that showed longer prophylactic treatment with Valcyte reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8 percent (for patients who received 100 days of treatment) to 16.8 percent (for patients who received treatment for 200 days) at one year after receiving a transplanted kidney (p Read more

Related support groups: Valcyte, Valganciclovir

Longer Antiviral Therapy Reduces Lung Transplant Complications

Posted 14 Jun 2010 by Drugs.com

MONDAY, June 14 – Extended antiviral treatment after a lung transplant may help prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows. A common cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes mild effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the drug valganciclovir (Valcyte) for up to three months. But even with this treatment, most lung transplant patients develop CMV infections within a year. The Duke study included 136 patients who completed three months of oral valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of oral valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly ... Read more

Related support groups: Organ Transplant, Valcyte, Valganciclovir

Extended Antiviral May Benefit Kidney Transplant Patients

Posted 2 Feb 2010 by Drugs.com

THURSDAY, Sept. 17 – A longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with a virus that can cause devastating problems, new research suggests. Healthy people can usually fight off the virus, called cytomegalovirus, but those with kidney transplants have weakened immune systems and are more susceptible to infection, the authors of the study noted in a news release from the American Society of Nephrology. In the comparison study, Dr. Fu Luan, of the University of Michigan in Ann Arbor, and colleagues gave kidney transplant patients either three months or six months of treatment with the antiviral drug valganciclovir. They found that those who were given the longer treatment had a rate of infection that was half that of those who received treatment for three months (12 percent vs. 24 percent). When the ... Read more

Related support groups: Cytomegalovirus (CMV) Infection, Valcyte, Valganciclovir

Ask a Question

Further Information

Related Condition Support Groups

Cytomegalovirus (CMV) Infection, CMV Retinitis

Related Drug Support Groups

Valcyte

Valganciclovir Patient Information at Drugs.com